ReviewFrontiers in human neuroscience2025
Research progress in unilateral moyamoya disease.
Review in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Moyamoya Vasculopathy and Atypical Moyamoya-like Patterns: Insights into Diagnosis and Therapeutic Implications.NeuroSci · 2026Review
- Indirect Revascularization for Pediatric Moyamoya Angiopathy: Insights from a Brazilian Cohort.Journal of clinical medicine · 2025Article
- Exploring the Real Mental Experience of Patients with Moyamoya Disease: A Qualitative Analysis.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unilateral moyamoya disease (U-MMD) is a chronic vascular disease characterized by progressive stenosis and occlusion of the terminal end of the internal carotid artery and its main branches, resulting in the appearance of moyamoya-like blood vessels at the base of the brain. The etiology of U-MMD is unknown, it accounts for 9.7-17.8% of all moyamoya disease, and the family incidence is 5.5-13.3%. The clinical characteristics are similar to those of typical moyamoya disease, but there are some differences. U-MMD can progress to bilateral moyamoya disease with a median probability of 29.01% (ranging from 6.3 to 58.8%), and there are many risk factors that promote its development. Surgical treatment can effectively reduce the incidence of ischemic stroke and improve prognosis. However, the timing and indications for surgery require further investigation. This article reviews the latest research progress on the etiology, epidemiology, clinical and radiological characteristics, progression, treatment, and prognosis of U-MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.